Physician profile
Robert J Duch
NPI 1609935436
$1,566.51
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $221 · 2021: $358.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $590.00 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $371.12 | 2019-2021 | |
| Amarin Pharma, INC. | $183.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $139.77 | 2019-2020 | |
| Astellas Pharma US INC | $67.17 | 2019-2021 | |
| Melinta Therapeutics, LLC | $66.36 | 2019 | |
| Scilex Pharmaceuticals INC. | $37.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.86 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $23.76 | 2021 | |
| Amgen INC. | $16.90 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.47 | 2020 | |
| Lilly USA, LLC | $13.18 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Duch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.